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MicroRNA-222 regulates muscle alternative splicing
through Rbm24 during differentiation of skeletal
muscle cells
B Cardinali1,5, M Cappella1,2,5, C Provenzano1, JM Garcia-Manteiga3, D Lazarevic3, D Cittaro3, F Martelli*,4 and G Falcone*,1
A number of microRNAs have been shown to regulate skeletal muscle development and differentiation. MicroRNA-222 is
downregulated during myogenic differentiation and its overexpression leads to alteration of muscle differentiation process and
specialized structures. By using RNA-induced silencing complex (RISC) pulldown followed by RNA sequencing, combined with in
silico microRNA target prediction, we have identified two new targets of microRNA-222 involved in the regulation of myogenic
differentiation, Ahnak and Rbm24. Specifically, the RNA-binding protein Rbm24 is a major regulator of muscle-specific alternative
splicing and its downregulation by microRNA-222 results in defective exon inclusion impairing the production of muscle-specific
isoforms of Coro6, Fxr1 and NACA transcripts. Reconstitution of normal levels of Rbm24 in cells overexpressing microRNA-222
rescues muscle-specific splicing. In conclusion, we have identified a new function of microRNA-222 leading to alteration of
myogenic differentiation at the level of alternative splicing, and we provide evidence that this effect is mediated by Rbm24 protein.
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During skeletal muscle differentiation, gene expression is
tightly regulated at both transcriptional and post-
transcriptional levels. MicroRNAs (miRNAs) have emerged
as key post-transcriptional modulators of gene expression in
virtually all biological processes, including myogenesis.1
A number of miRNAs have been implicated in myogenesis
and muscle disease, some specifically expressed in
muscle cells, others ubiquitously expressed.2,3 Two closely
related miRNAs, miR-221 and miR-222, were previously
shown to be downmodulated during differentiation and to
induce a delay in progression of differentiation and alterations
of myotube morphology and contractile structures when
overexpressed.4 MiR-221 and miR-222 are clustered together
in both human and mouse genomic loci, are evolutionarily
conserved among vertebrates, have similar sequences and an
identical target binding ‘seed’ region, corresponding to
positions 2–8, in both humans and mice. They are ubiquitous
and have been found abnormally expressed in several
tumors.5 In muscle cells, miR-221/222 have been shown to
target p27 (Cdkn1b),4 β1-syntrophin (Sntb1)6 and, more
recently, MyoD transcription factor.7 In addition, an increase
in miR-221/222 expression was described in muscles from
mdx dystrophic mice and in muscle tissues from several
human primary muscle disorders,8,9 linking these miRNAs to
muscle disease.
MiRNAs are excised from large stem-loop-containing
transcripts and then incorporated into RNA-induced silencing
complex (RISC), where they silence target transcripts via
translational repression and/or mRNA destabilization.1,10
MiRNAs typically bind to target mRNA 3’UTRs containing
short stretches of complementarity to the seed region of the
miRNA.11 MiRNA target sites in mRNA 5'UTRs and coding
regions have also been found, although less commonly.12
Through this minimal degree of base pairing, miRNAs can
potentially regulate many different transcripts within the same
cellular pathways in a coordinated fashion. At the same
time, however, this poses the question of identifying biologi-
cally relevant miRNA–target interactions. Computational
approaches for miRNA target prediction are important tools
to narrow down the number of putative targets although they
tend to overpredict miRNA-binding sites. Overexpression of
miRNAs followed by transcriptome analyses is frequently
used to identify miRNA–mRNA interactions and their
relevance for phenotypic changes. However, this approach
presents some limitations, as effects on primary miRNA
targets cannot be distinguished from indirect effects on gene
expression, and miRNA targets that are regulated solely by
translational repression are missed.13 Thus, search for
'functional' miRNAs, actually associated to the RISC and
engaged in mRNA target modulation, possibly combined with
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bioinformatic target prediction tools, may prove more useful.
Indeed, recent literature reports highlight the important role of
the RISC immunoprecipitation (RISC-IP) technique in identify-
ing functionally relevant miRNA targets both in cell culture
systems14,15 and in human brain tissue.16
In order to identify among the predicted miR-222 targets
those specifically involved in skeletal myogenesis, we
combined in silico target prediction with RISC-IP followed by
next-generation sequencing of co-precipitated RNAs17–19
using primary mouse satellite cells (MSC) ectopically expres-
sing miR-222, as myogenic cell model. This approach allowed
us to discover and functionally validate a number of miR-222
target transcripts. In particular, we show here that Rbm24, a
muscle-specific RNA-binding protein having a major role in
regulation of muscle development and differentiation20–23 is a
direct target of miR-222 and its inhibition by miR-222 impairs
muscle-specific alternative splicing.
Results
RNA sequencing and validation of miR-222 targets in
skeletal muscle cells. We have developed a target immu-
nopurification method based on the immunoprecipitation of
endogenous RISC complexes enriched for miR-222 and its
target mRNAs, using antibodies specific for Ago2, a core
component of the RISC. A number of preliminary experiments
were performed in post-mitotic MSC myocytes to optimize the
RISC-IP conditions. The RISC-IP efficiency was checked by
western blot analysis of immunoprecipitated Ago2 protein (IP)
compared with total Ago2 before IP (input) and to that
remaining in the supernatant after IP (super) (Supplementary
Figure S1a). Specific enrichment of known miR-222 target
mRNAs such as p27 and p57 (Cdkn1c), was assessed by
quantitative PCR (qPCR) analysis of RNAs in RISC-IP
complexes from miR-222-overexpressing cells (miR-222-IP)
compared with RNAs in RISC-IP from control duplexes
transfected cells (control-IP) (Supplementary Figure S1b). In
order to minimize possible off-target effects on RISC due to
excessive overexpression of transfected miR-222 mimics, we
set up the miR-222 duplex concentration such to ensure that
the specific enrichment of miR-222 on miR-222-IPs was
below 10-fold compared with the endogenous miR-222
detected in control-IP, despite being 4100 times in the input
RNA (Supplementary Figure S2).
To identify potential mRNA targets of miR-222, RISC-IP
RNAs from MSC myocytes transfected with miR-222 and
control duplexes from two independent experiments were
analyzed by RNA Sequencing. In this way, a total of 10998
peaks corresponding to 5626 different genes were identified
(Supplementary Table S1). The number of peaks exceeded
that of the genes as, for some transcripts, more than one peak
region was identified, as also previously reported,16 in keeping
with the fact that a single RNA species can bear more than one
miRNA-binding site. Next, putative targets of miR-222 were
selected among the RNAs overrepresented in RISC
complexes from miR-222-overexpressing cells. To maximize
sensitivity and minimize possible biases, a very low cutoff
value was adopted (log2 fold change 40). Specificity was
ensured by taking into account only transcripts displaying
potential miR-222-binding sites and by the following
validation step. Using miRanda miRNA target prediction
software,24 we found that sequence peaks corresponding
to 234 different RNAs contained the seed for miR-222
and were overrepresented in miR-222-overexpressing cells
(Supplementary Table S2). Among these, six were selected on
the basis of their enrichment, gene function and/or relevance
for myogenic differentiation, and were validated by qPCR in
new RISC-IP experiments (Figure 1 and Table 1). In Figure 1,
the average fold increase of the target transcripts in
miR-222-IPs compared with control-IPs is shown together
with that of the known miR-222 target p27, included for
reference. To test whether the increase of these six mRNAs
was not simply a reflection of increased total level upon
miR-222 expression, RNA extracted from IP input was
analyzed. We found that mRNA levels of D1Pas1 and Ahnak
were decreased, whereas the other transcripts were not
modulated (Supplementary Figure S3). Interestingly, the peak
sequences referring to the Chrng gene (Supplementary
Table S1) were contained in the 3’UTR of a predicted but not
yet verified transcript variant, containing a longer 3’UTR
compared with the annotated and sequenced mRNA. We
confirmed the existence of such transcript by RT-PCR in both
MSC and C2C12 myoblasts (Supplementary Figure S4).
Ahnak and Rbm24 are novel targets of miR-222 in
skeletal muscle cells. Two new potential targets of
miR-222 appeared particularly interesting for their pivotal
role in myogenic differentiation: Ahnak and Rbm24. Ahnak is
a 700 kD large protein belonging to the family of scaffold
proteins containing the PDZ protein-interaction domain,
involved in regulation of calcium channels, cell architecture
and migration and highly expressed in skeletal and cardiac
muscle (reviewed in ref. 25). Rbm24 is a 20–25 kD small
RNA-binding protein required for cardiac and skeletal muscle
development and preferentially expressed in striated muscle
Figure 1 qPCR validation of miR-222 mRNA targets enriched in RISC-IP. MSC
myocytes, kept in DM for 30 h, were transfected with 20 nM miR-222 mimic and
control siGFP and, after 16 h, processed for RISC-IP. RNA extracted from the IPs
were analyzed by qPCR for the enrichment of selected miR-222 mRNA targets. p27
mRNA is included for comparison. Values were normalized to GAPDHmRNA and the
expression level of each mRNA is indicated as fold change in miR-222-IPs versus
control-IPs, referred as 1. The error bars represent the average± S.E. (n⩾ 3–4;
*Po0.05; **Po0.01; ***Po0.001)
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where it stabilizes muscle regulatory mRNAs and regulates
muscle-specific alternative splicing.20–23
To confirm that miR-222 regulates Ahnak and Rbm24
protein expression, we performed experiments of miR-222
overexpression and inhibition in MSC cells. Transfection of
myocytes with miR-222 mimic led to a significantly decreased
expression of Ahnak and Rbm24 proteins in western blot
analysis, whereas transfection with antisense miR-222
inhibitors resulted in the upregulation of Ahnak and Rbm24
protein expression compared with transfected control RNA
(Figures 2a and b).
Ahnak mRNA contains a miR-222-binding site in the coding
region, whereas Rbm24 mRNA contains two miR-222-binding
sites in the 3’UTR (Rb-1 and Rb-2), the most downstream
(Rb-2) being that found by RNA sequencing. To show that
miR-222 directly regulates the expression of Ahnak and
Rbm24 transcripts, miR-222 seed-pairing sites and the
immediately surrounding sequences contained in Ahnak and
Rbm24 were cloned downstream of the luciferase open-
reading frame of the pMIR-REPORT vector. These constructs
along with either miR-222 mimic or a control duplex RNAwere
transfected in 293FT cells and the luciferase activity was
measured 24 h later. Figure 2c shows that miR-222 inhibited
the expression of the reporter constructs containing an intact
miR-222-binding site of Ahnak, whereas this effect was
prevented in the construct containing a deletion in the same
site. Similarly, both miR-222 seed-pairing sites of Rbm24, but
not their mutated versions, were targeted by miR-222. In
addition, to analyze the effect of miR-222 on both sites
simultaneously, a portion of the 3’UTR of Rbm24 containing
both miR-222-binding sites was cloned downstream of the
luciferase coding region of pGL3 reporter vector and luciferase
expression showed a downmodulation comparable to that of
the single sites, and absent in the mutated version. As a
reference, the 3’UTR of p27, a well-established miR-222
target4,26 was analyzed, displaying a degree of repression
upon miR-222 overexpression similar to that of Rbm24
(Figure 2d). These results confirm that miR-222 directly
inhibits Ahnak and Rbm24 target transcripts.
Overexpression of miR-222 and silencing of Rbm24
result in inhibition of myoblast fusion and muscle
alternative splicing. We chose to focus our studies on
Rbm24, as modulation of this protein by miR-222 appears
more effective. To verify that Rbm24 is upregulated upon
differentiation in MSC, we analyzed Rbm24 expression
during differentiation at both mRNA and protein levels, and
compared it with that of miR-222. Figure 3 shows the analysis
of Rbm24, p27 and muscle-specific Myogenin proteins in
growing conditions (growth medium, GM) and at different
times following shift to differentiation conditions (differentia-
tion medium, DM), in parallel with Rbm24 and p27 mRNAs,
and miR-222, analyzed by qPCR. Myoblasts were plated at
low density in GM, as it is known that accumulation of p27 is
dependent on cell density in GM.27 The results show an
inverse expression of Rbm24 or p27 proteins and miR-222
upon differentiation, as expected for miR-222 targets
(Figures 3a and d). However, levels of Rbm24 and p27
mRNA show a clear difference upon differentiation, as
Rbm24 transcript accumulation was very low in GM
compared with DM, whereas that of p27 slightly decreased
in DM (Figures 3b and c). This suggests that in myoblasts
Rbm24 is regulated mostly at transcriptional level, whereas
p27 is repressed posttranscriptionally.
In order to determine whether downregulation of Rbm24
contributed to miR-222-inhibition of myogenesis, we decided
to investigate whether overexpression of miR-222 and
inhibition of Rbm24 by RNAi could exert similar effects
on differentiation. To this aim, we transfected miR-222,
siRbm24 or control duplex RNAs in proliferating myoblasts,
allowed them to differentiate and analyzed the percentage of
fusion and the number of myosin-positive cells. Silencing of
Rbm24 by RNAi or by miR-222 overexpression resulted in a
similar impairment of myoblast fusion, whereas the
number of myosin-positive cells was only slightly affected by
both treatments (Figure 4). Inhibition of Rbm24 protein
accumulation by miR-222 and siRbm24 was verified by
western blot after 24 h in DM in a parallel experiment
(Figure 5a).
As Rbm24 has an important role in regulation of muscle
alternative splicing of several transcripts during skeletal
muscle differentiation,23 we asked whether miR-222 over-
expression could also affect muscle-specific splicing. MSC
myoblasts were transfected with miR-222, siRbm24 or control
duplex RNAs, shifted to differentiation conditions and, after 8,
16 and 24 h, cells were subjected to western blot analysis to
check downregulation of Rbm24 protein and to PCR analysis
to measure the efficiency of muscle alternative splicing of
mRNAs coding for Coro6, Fxr1 and NACA. These proteins
have important roles in skeletal muscle formation and
Table 1 Validated miR-222 target transcripts
Gene
symbol
RefSeq Average log2 fold
change
Target sequence
position
Known functionsa
Ahnak NM_009643 0.45 Coding Regulation of actin cytoskeleton, calcium channels and skeletal
muscle costameres
Chrng XM_006529078 0.32 3'UTR Cholinergic receptor activity, protein binding
D1Pas1 NM_033077 0.51 3'UTR ATP binding, DNA/RNA binding
Myo10 NM_019472 0.26 3'UTR Actin binding, ATPbinding, regulation of cell adhesion andmigration
Rbm24 NM_001081425 0.23 3'UTR RNA binding, regulation of mRNA stability, regulation of muscle
alternative splicing
Wbp5 NM_011712 0.28 Coding-3'UTR
junction
Protein binding
aFrom NCBI Database.
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regeneration28–30 and the processing of their transcripts
was shown to be regulated by Rbm24 during skeletal muscle
differentiation.23 Overexpression of miR-222 inhibited
efficiently accumulation of Rbm24 and p27 proteins already
at 8 h post differentiation, whereas siRbm24 specifically
inhibited only Rbm24 protein accumulation, best at 16 h and
24 h post differentiation. Inhibition of Myogenin accumulation
was also observed in miR-222 overexpressing cells, possibly
as an indirect consequence of miR-222 effect on other targets
(Figure 5a). Exon inclusion yielding the muscle-specific
isoforms of Coro6, Fxr1 and NACA mRNAs was inhibited by
both miR-222 overexpression and Rbm24 RNAi with compar-
able efficiency. Indeed, increased accumulation of the general
isoforms and decrease of the muscle-specific isoforms are
well detectable at 16 h and 24 h for Coro6 and Fxr1, and
already at 8 h for skNAC, as compared with cells transfected
with control duplex RNA (Figures 5b and c).
In order to determine whether inhibition of p27 by miR-222
could also be involved in regulation of Rbm24 expression and,
in turn, of myoblast fusion and muscle alternative splicing, we
analyzed the effects of miR-222 overexpression and p27
inhibition by RNAi in parallel. These experiments demon-
strated that inhibition of p27 did not affect accumulation of
Rbm24 protein and, conversely, Rbm24 RNAi did not alter p27
expression level (Supplementary Figure S5c). Moreover, in
contrast to miR-222 overexpression and siRbm24, neither
Figure 2 Validation of Ahnak and Rbm24 as direct targets of miR-222. (a, b) MSC myocytes, kept in DM for 30 h, were transfected with miR-222 mimic (222) or antisense
inhibitors (α-222) and relative controls siGFP or anti GFP (CTL). After 48 h, cells were lysed for protein analysis. Western blot analysis of Ahnak (a) and Rbm24 (b) expression
levels; Nucleoporin (NUP) and p38 proteins were used as loading controls. The histograms in (a) and (b) (lower panels) show the quantitation of expression levels of Ahnak and
Rbm24, normalized to Nucleoporin and p38, in myocytes transfected with miR-222 mimic or inhibitor versusmyocytes transfected with control RNAs, referred as 1. The error bars
represent the average± S.E. (n= 3–6; *Po0.05; **Po0.01; ***Po0.001). (c) 293FT cells were transfected with empty firefly luciferase reporter vector (pMIR-REPORT) or
derived constructs containing either an intact miR-222-binding site (wt), or a mutated miR-222-binding site (mut) in Ahnak and Rbm24 target regions. For Rbm24 both miR-222
target sites were analyzed (Rb-1, Rb-2). (d) 293FT cells were transfected with empty firefly luciferase reporter vector (pGL3) or derived constructs containing an intact portion of
the 3’UTR of Rbm24 (RbUtr wt) or p27 ( p27Utr wt) or mutated 3’UTRs (mut). (c, d) Each plasmid was co-transfected with a plasmid encoding renilla luciferase along with
miR-222 mimic or negative control (CTL). Activities of each pMIR-REPORT and pGL3 construct were normalized first to renilla luciferase and then to empty vector activities. The
ratio of luciferase activity in cells transfected with miR-222 mimic versus cells transfected with control RNA is expressed as fold change. The error bars represent the average±
S.E. (n= 3–5; **Po0.01; ***Po0.001)
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myoblast fusion nor muscle alternative splicing were affected
by p27 RNAi (Supplementary Figure S5a, b and d).
These results clearly show that decreased accumulation of
Rbm24 by means of either miR-222 overexpression or Rbm24
RNAi results in comparable inhibition of myoblasts fusion and
muscle-specific alternative splicing, suggesting that the
inhibitory effect of miR-222 is mediated by modulation
of Rbm24.
Ectopic expression of Rbm24 rescues miR-222-
dependent inhibition of muscle alternative splicing. To
assess the specific contribution of Rbm24 to the effect of
miR-222 on muscle alternative splicing, we generated a
lentiviral vector containing the coding region of Rbm24 (Lenti-
Rbm24). The cloned allele lacked the 3’UTR region and
therefore was unresponsive to miR-222 regulation. Proliferat-
ing myoblasts were infected with Lenti-Rbm24 or a control
Lenti-GFP (green fluorescent protein), maintained in GM for
48 h to allow for protein expression. Then, cells were either
processed for analysis of exogenous Rbm24 protein accu-
mulation or transfected with miR-222 or control duplex RNAs
and shifted to DM for 24 h to test for splicing efficiency.
Western blot analysis confirmed ectopic expression of
Rbm24 protein in GM, where the endogenous protein is
barely expressed, and in DM, where its expression adds up to
the endogenous form (Figures 6a and b). In miR-222 mimic-
transfected cells, lentiviral expression of ectopic Rbm24
reconstituted the physiological levels of the protein, as
expression from the endogenous transcript is inhibited
(Figures 6a and b). The rescued expression of Rbm24
resulted in increased accumulation of the muscle-specific
isoforms of Coro6, Fxr1 and NACA transcripts (Figures 6c
and d), confirming that miR-222 inhibits exon inclusion
through downregulation of Rbm24. Interestingly, in the
presence of miR-222, ectopic Rbm24 did not recover the
expression of p27, as expected, being p27 a direct miR-222
target, and did not induce a significant increase in Myogenin
accumulation (Figures 6a and b), indicating that regulation of
this protein was not dependent on Rbm24 in this context.
Discussion
The identification of biologically important targets is crucial for
understanding miRNA function. In silico miRNA target predic-
tion tools combined with biochemical pulldown techniques
such as RISC-IP, followed by RNA sequencing, provide a
specific and sensitive method for identifying miRNA targets.
However, one potential limitation is represented by the low
efficiency of the current bioinformatic algorithms to identify non
canonical, 'seedless' targets.31 Most studies on miR-222
targets have focused on cancer-related pathways, being this
miRNA deregulated in many cancer types.5 In this study, we
searched for miR-222 targets in skeletal muscle cells to
identify miR-222-regulated pathways in myogenesis, and
assuming that muscle-specific targets could be identified only
in a myogenic cell context.
By using this approach, we have been able to identify and
validate by qPCR a number of miR-222 target transcripts, two
of which were further studied for their crucial roles on skeletal
myogenesis. Ahnak contains a miR-222 target sequence in
Figure 3 Expression of Rbm24, miR-222 and muscle-specific genes
during myogenic differentiation. (a) Proliferating MSC myoblasts (GM) and myoblasts
shifted to DM for 16–72 h were analyzed at different time points for expression of
Rbm24, p27 and Myogenin proteins by western blot. p38 is shown as loading
control. The table shows a quantification of the expression of Rbm24, p27 and
Myogenin proteins in DM, normalized to p38, relative to GM, referred as 1.
(b–d) Parallel cell cultures were analyzed for expression of Rbm24 mRNA, p27
mRNA and miR-222 by qPCR. Values were normalized for expression of GAPDH
mRNA and miR-16, respectively, and shown as fold change relative to GM, referred
as 1. The error bars represent the average±S.E. (n= 3–4; *Po0.05; **Po0.01;
***Po0.001)
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the coding region. There are many examples of transcripts
containing miRNA target sites in the coding region, which are
translationally regulated.12 It is hypothesized that these sites
may be recruited when the 3’UTR of the target gene is too
short or to tune the protein abundance of alternative splice
variants.12We have shown that Ahnak target site is responsive
to miR-222 in luciferase reporter assays and that Ahnak
protein is modulated following miR-222 overexpression and
inhibition in muscle cells. Further experiments are needed to
define how downregulation of Ahnak by miR-222 impacts on
muscle differentiation. Similarly, we have shown that both
miR-222-binding sites of Rbm24 are responsive to miR-222
in luciferase reporter assays, either separately or in combina-
tion, and that the protein is modulated by miR-222
overexpression and inhibition. However, Rbm24 transcript
stability is not affected by overexpression of miR-222, implying
that this target would have not been identified by using a
transcriptome analysis approach. As Rbm24 mRNA and
miR-222 are inversely regulated upon differentiation of muscle
cells, it is likely that miR-222 contributes to ensure a low
expression level of the protein in proliferating myoblasts.
Notably, upon differentiation Rbm24 transcript is highly
upregulated, in contrast to p27. This suggests that Rbm24 is
mostly transcriptionally regulated, whereas p27 is translation-
ally repressed in myoblasts.
We showhere that overexpression of miR-222 and silencing
of Rbm24 result in inhibition of myoblast fusion. Rbm24
silencing was previously shown to inhibit fusion of C2C12
myoblasts undergoing differentiation20 and we observe a
similar effect in MSC, confirming that Rbm24 is required for
myoblast fusion. However, inhibition of myotube formation by
miR-222 does not appear to be mediated solely by Rbm24, as
ectopic expression of the protein does not result in enhanced
fusion (data not shown). As previously reported in other
myogenic contexts,4,7 overexpression of miR-222 results in
inhibition of Myogenin accumulation also in MSC. However, in
Figure 4 MiR-222 overexpression and Rbm24 silencing inhibit myoblast fusion. (a) MSC myoblasts transfected in GM with siGFP, miR-222 or siRbm24 duplex RNAs were
maintained in GM for 1 day (GM) or shifted to DM for 1 day (1d) or 2 days (2d). Cells were subjected to immunofluorescence with antibodies specific for skeletal Myosin Heavy
Chain (MHC) and nuclei were counterstained with Hoechst dye. Scale bar: 100 μm. (b) Quantitation of fusion and MHC-positive (MHC+) cells in DM at 1d and 2d in at least three
independent experiments (averages± S.E.) is shown in the table. The percentage of fusion was calculated as the ratio of nuclei in MHC+ myotubes containing three or more
nuclei over total nuclei given as 100%; at least 500 nuclei were counted for each plate
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contrast to a previous report in C2C12myoblasts,21 inMSCwe
do not observe amodulation in Myogenin expression following
Rbm24 silencing or ectopic expression in the presence of
miR-222 mimics. This is not surprising as it is well known that
miRNAs affects many targets at the same time, and it is
presumable that miR-222 inhibitory effect on Myogenin
expression is mediated by other targets such as MyoD.7
As it was previously shown that downregulation of p27
affects myoblast fusion and myosin accumulation,27 we asked
whether p27 could regulate Rbm24 expression and found that
p27 silencing neither alters Rbm24 protein accumulation nor
myoblast fusion and muscle-specific alternative splicing,
implying that the two proteins have different roles in regulation
of differentiation. These contrasting results on the effects of
p27 can possibly be explained by the use of a different cell
model (C2C12 immortalized myoblasts) and different experi-
mental conditions (transfection at high cell density).
It has been reported that skeletal muscle is one of the
tissues with the highest number of alternative splicing events,
required for the expression of muscle-specific protein isoforms
essential for muscle development and function.32,33 Some
forms of muscle disease are associated to aberrant alternative
splicing. In particular, in Myotonic Dystrophies triplet expan-
sion within non-coding region of RNAs alters either the activity
or the expression of the splicing regulators MBNL1 and
CUGBP132 and genome-wide analysis of muscle biopsies
from Myotonic Dystrophy type 2-affected patients revealed
hundreds of aberrant alternative splicing events.34 Notably,
miR-222 expression levels were found increased in several
muscular dystrophies.8 Here, we show that targeting Rbm24
by miR-222 is a crucial event in inhibition of muscle-specific
transcript production. It is likely that, in addition to Coro6, Frx1
and NACA, miR-222 can regulate the expression of other
muscle-specific proteins, important for muscle development
and function, through modulation of Rbm24 expression during
differentiation. Regulation of alternative splicing by miRNAs
during muscle development was previously reported for
muscle-specific miR-133. In contrast to miR-222, miR-133 is
upregulated during myogenic differentiation and was shown to
repress polypyrimidine tract-binding protein (PTB), an inhibitor
of early muscle-specific splicing.35 Interestingly, PTB antag-
onizes Rbm24 in promoting muscle-specific exon inclusion.23
The number of miR-222 targets involved in skeletal muscle
cell differentiation is constantly increasing, and we describe
here two new ones. All miR-222 validated targets have
important functions in many processes required for myogen-
esis such as lineage determination and mainteinance
(MyoD7), control of proliferation (p274), regulation of dystro-
phin complexes and costameres (β1-syntrophin;6 Ahnak, this
work) and regulation of muscle-specific alternative splicing
(Rbm24, this work). Importantly, we have identified a new
function of microRNA-222 leading to alteration of myogenic
differentiation at the level of alternative splicing, and we show
that this effect is mediated by Rbm24 protein.
These findings altogether highlight the important role of
miR-222 in controlling myogenesis. The number of muscle-
related miR-222 targets is going to increase in the next future
and our list of overrepresented RNAs in RISC-IP from
miR-222-overexpressing myocytes is a source of other
miR-222 potential targets, whichmay be relevant for regulation
of myogenesis.
Materials and Methods
Antibodies. Mouse monoclonal antibody (mAb) anti-Ago2 (MA2) was a gift from
Dr. O’Carrol. mAb to p27 was from BD Transduction Laboratories (Franklin Lakes,
NJ, USA), and rabbit polyclonal Ab to p38 (C-20) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). mAbs to Nucleoporin 153 (QE5) and to
Figure 5 MiR-222 overexpression and Rbm24 silencing inhibit muscle alternative
splicing during early myoblasts differentiation. (a) MSC myoblasts transfected in GM
with siGFP (siGFP), miR-222 (222) or siRbm24 (siRbm) duplex RNAs were shifted to
DM for 8 h, 16 h or 24 h and analyzed for expression of Rbm24, p27 and Myogenin
proteins by western blot. The table shows a quantification of the expression of
Rbm24, p27 and Myogenin proteins normalized to p38, relative to control siGFP,
referred as 1. Untransfected MSC in GM (GMnt) and DM (DMnt) at 24 h are shown for
comparison. (b) RNA from parallel cell cultures was analyzed by semi-quantitative
RT-PCR and amplicons were separated on ethidium bromide-stained agarose gels to
determine splicing efficiency of muscular isoforms of Coro6 and Fxr1 transcripts.
Greyscale of images was inverted for a sharper band definition. In the scheme, the
black rectangles represent muscle-specific exons and the black arrows indicate
primer positions. (c) General and muscular isoforms of NACA transcripts were
detected by qPCR analysis and normalized to GAPDH transcript. Expression of
muscle-specific isoform of NACA (skNAC) over the general NACA isoform, and
relative to siGFP, referred as 1, is shown in the histogram. A representative
experiment is shown
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Ahnak (EM-09) and rabbit polyclonal Ab to RBM24 (94567) were from Abcam
(Cambridge, UK). mAb to Myosin Heavy Chain (MF20) was obtained from
Dr. Fischman and mAb to myogenin (F5D) was a gift from G Cossu.
TRITC-conjugated goat anti-mouse antibodies were from Jackson ImmunoRe-
search Laboratories (West Grove, PA, USA). Horseradish peroxidase-conjugated
goat anti-mouse and anti-rabbit antibodies were from Santa Cruz Biotechnology.
miRNA mimics, siRNAs and antisense oligonucleotides. miR-222
and control MirVana mimics were hsa-miR-222-3p and Negative Control #1 from
Ambion, Thermo Scientific (Waltham, MA, USA). Alternatively, siRNA-like miR-222
mimic and siGFP control RNA duplex (Eurofins, Luxembourg, Luxembourg,
described in4) were used. 20-O-Me antisense RNA oligonucleotides anti miR-222
and anti GFP as control were purchased from Eurofins,4 whereas siRNA for Rbm24
was Mission Pre-designed siRNA (PDSIRNA2D) from SIGMA-ALDRICH
(St. Louis, MO, USA). The antisense sequence of the Individual siGenome duplex
(Dharmacon, Lafayette, CO, USA) for mouse p27 was 5′-UAUCCCGGCAGUG
CUUCUCUU-3′.
Plasmid construction. To prepare the Rbm24 lentiviral construct, the coding
region of Rbm24 (RefSeq NM_001081425) was amplified by RT-PCR from total
RNA of differentiated MSC using the primers described in Supplementary Table S3,
also containing the AgeI and SalI restriction sites. The PCR product was inserted
into pCR2.1 (TA Cloning Kit, Thermo Scientific), excised by AgeI and SalI digestion
and then cloned into the AgeI and SalI sites of pCCLsin.PPT.hPGK.GFP,36 here
named Lenti-GFP, by replacing GFP.
To construct the luciferase reporter plasmids (pMIR-Ahn wt, pMIR-Ahn mut, pMIR-
Rbm-1 wt, pMIR-Rbm-2 wt, pMIR-Rbm-1 mut, pMIR-Rbm-2 mut), synthetic oligos
(Supplementary Table S3) corresponding to 58 nt surrounding the predicted miR-222
target sites (wt) or the same sequence deleted of the 7 nt matching the miR-222
seed sequence (mut) of Ahnak (RefSeq NM_009643.2) and Rbm24 (RefSeq
NM_001081425), were cloned into the SpeI and HindIII restriction sites of the pMIR-
REPORT Luciferase vector (Ambion, Thermo Scientific). To generate the
Rbm24-3’UTR luciferase reporter plasmid, a 959 bp fragment containing two
putative miR-222-binding sites was amplified by PCR from differentiated MSC cDNA,
using the primers described in Supplementary Table S2. Following SpeI digestion, the
PCR product was cloned downstream of the firefly luciferase coding sequence in
the pGL3-Promoter vector (Promega, Fitchburg, WI, USA) into the XbaI restriction
site. The Rbm24-3’UTR fragment was cloned in sense (pRbm-UTR wt) and antisense
orientation (pRbm-UTR mut).
Cell cultures, duplex RNA transfections and viral infections.
Primary MSC37 were grown in Ham’s medium supplemented with 20% fetal bovine
serum, 3% chicken embryo extract and 2.5 ng/ml basic fibroblast growth factor on
collagen-coated dishes. C2C1238 were maintained proliferating in Dulbecco's
Modified Eagle medium (DMEM) supplemented with 20% fetal bovine serum (GM).
Differentiation of MSC and C2C12 myoblasts was induced by incubating the cultures
Figure 6 Ectopic expression of Rbm24 rescues muscle alternative splicing inhibited by miR-222. (a) MSC myoblasts were infected with Lenti-GFP and Lenti-Rbm24 and
grown in GM for 48 h (GM). Parallel cultures were transfected with miR-222 mimic (222) and negative control duplex RNA (CTL) and shifted to DM for 24 h. Cells were analyzed
for expression of Rbm24, p27 and Myogenin proteins by western blot. (b) The histogram shows the quantitation of the expression levels of Rbm24, p27 and Myogenin normalized
to p38, relative to MSC infected with Lenti-GFP and transfected with control duplex RNA, referred as 1, in three independent experiments. The error bars represent the
average± S.E. (c) RNAs from parallel cell cultures were analyzed by semi-quantitative RT-PCR, and amplicons were separated on ethidium bromide-stained agarose gels to
determine splicing efficiency of muscular isoforms of Coro6 and Fxr1 transcripts. Two different exposures of the same amplified bands for Coro6 or amplification at different PCR
cycles for Frx1 are shown, to better highlight differences in the muscle-specific isoforms (top panels, black arrows) and in the general isoforms (bottom panels, white arrows). (d)
Real-time PCR analysis to detect general and muscular isoforms of NACA transcripts normalized to GAPDH transcript. The histogram shows expression of muscle-specific
isoform of NACA (skNAC) over the general isoform, and relative to Lenti-GFP transfected with control duplex RNA, referred as 1, in three independent experiments. The error bars
represent the average± S.E.
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in DMEM supplemented with 2% heat-inactivated horse serum (DM). MSC
myoblasts were transfected with 10–25 nM duplex RNAs (siRNA or miR-222 mimics
and controls) or 25–50 nM 20-O-Methyl antisense RNA oligonucleotides using the
Lipofectamine 2000 transfection reagent (Invitrogen, Thermo Scientific, Carlsbad,
CA, USA) in serum-free Optimem (Gibco-BRL, Thermo Scientific, USA). MSC
myoblasts were transfected either in GM for 4–5 h and transferred to DM for
different times, or shifted to DM for 24–30 h and then transfected for 5 h to
overnight. 293FT cells (Invitrogen, Thermo Scientific) were grown in DMEM
supplemented with 10% fetal bovine serum and used for both lentivirus production
and luciferase assays. For production of Lenti-GFP36 and Lenti-Rbm24, 5 × 106 cells
per 100-mm plate were plated and, the following day, transfected with the lentiviral
construct plasmids and packaging mix plasmids (pMD2.VSVG,39 pMDLg/pRRE and
pRSV-Rev36) using the Lipofectamine 2000 reagent. Virus containing supernatant
was harvested 48 h and 72 h later and used to infect MSC cells (1 ml per 35-mm
plate) along with 2 μg/ml of Polybrene. Virus expression was monitored by western
blot analysis of GFP and Rbm24 proteins.
Ago2 immunoprecipitation. MSC myocytes kept in DM for 30 h were
transfected with 20 nM miR-222 or siGFP duplex RNAs using Lipofectamine 2000
reagent (Invitrogen, Thermo Scientific) and maintained in DM for a further 16 h.
After cell lysis, two lysate aliquotes were taken to analyze total RNAs and proteins
and the remaining was immunoprecipitated with anti-Ago2 antibody using the
RNA-binding protein immunoprecipitation Magna RIP Kit (Merck Millipore, Billerica,
MA, USA) following the manufacturer’s instructions. Ago2 bound RNA was extracted
using TRIzol reagent (Invitrogen, Thermo Scientific).
RNA sequencing. Amplification of cDNA from Ago2 co-immunoprecipitated
RNA was performed using the Ovation RNA-Seq system V2 (Nugen, San Carlos,
CA, USA), then cDNA was fragmented and ligated into a sequencing library using
Ovation Ultralow library system (Nugen). After barcoding, the RNA libraries were
pooled, denatured and diluted to a 8 pM final concentration. Cluster formation was
performed on cBot (Illumina, San Diego, CA, USA) (paired-end) using flow cells v.3.
The SBS (sequencing by synthesis) was performed according to TruSeq PE
protocol (Illumina) for the HiSeq 2500 (Illumina) set to 2 × 100 cycles, yielding an
average of 30 × 106 clusters for each sample. RNA sequencing data are archived in
the Gene Expression Omnibus database (GEO entry GSE75981, http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE75981). Analysis of count data was
performed using htseq-count (v0.5.3p9) and DESeq240 after reads were aligned
to the mouse genome (mm10) using SOAPSplice.41 In brief, DESeq2 uses
generalized linear models based in the negative binomial distribution. We built linear
models using two different experiments and two conditions (miR-222 over-
expression (n= 1) and control siRNA (n= 2)) with the linear formula (~ condition
+experiment).
Detection of putative targets. In order to find putative miR-222 seeds
within target mRNAs immunoprecipitated with RISC complexes, we identified
RNA-Seq enrichments using a peak calling approach. In brief, all aligned reads
(bam format) were transformed into bed files using bedtools (version 2.17.0) and
peaks were called using macs2 with default parameters. Peaks were filtered by a
log10p.value420, in order to enforce trustable enrichments. Peaks coming from the
different samples were merged in a single bed file containing all peaks. They were
then annotated using the mm10 bed annotation file from Ensembl (Mus_musculus.
GRCm38.72.gtf). Read counts over the identified intervals were assessed using
bedtools. miRanda software for microRNA target prediction42 was used to search for
miR-222 putative targets on the peak sequences detected at RISC-IP RNA. Genes
with peaks overrepresented in miR-222-overexpressing cells (log2 Fold Change
40) in two independent experiments with miRanda detected seeds for miR-222
were considered for further validation.
RNA expression analysis. Total and immunoprecipitated RNAs were
extracted with TRIzol reagent (Invitrogen, Thermo Scientific) and retro-transcribed
with the GoScript Reverse Transcription System (Promega) using oligo (dT) and
random primers. Specific primers for mRNA analysis by PCR are shown in
Supplementary Table S3. qPCR was performed using an Applied Biosystem 7500
Fast Real-Time PCR System. Power SYBR Green PCR master mix (Applied
Biosystems, Thermo Scientific, Waltham, MA, USA) was used to analyze mRNAs
and quantification was based on the standard curve method. Results were
normalized with respect to GAPDH expression. The analysis of different isoforms of
alternatively spliced mRNAs was performed by RT-PCR using GoTaq Flexi DNA
Polymerase (Promega) for 25–30 cycles for Coro6 and 30–35 cycles for Fxr1.
microRNA levels were analyzed from total RNA using the TaqMan MicroRNA
Assays (Applied Biosystems, Thermo Scientific). Relative expression was calculated
using the comparative Ct method (2−ΔΔCt).43 Different samples were normalized to
miR-16 expression.
Luciferase assays. For the expression of luciferase reporter constructs,
7 ×104 293FT cells were plated on Poly-L-Lysine (20 μg/ml, L7240 Biochrom, Berlin,
Germany) coated 48-multiwell plates and transfected with 7.5 ng of pMIR-Report or
pGL3-Promoter and derived plasmids, along with 7.5 ng of pRL plasmid coding for
renilla luciferase (Promega) to normalize for transfection efficiency (pRL-CMV in
co-trasfection with pMIR, pRL-SV40 in co-trasfection with pGL3). In total, 0.4 μl/well
of the lipofectamine 2000 reagent were used (Invitrogen, Thermo Scientific). In
some experiments, a pGL3 construct containing the human p27 3’UTR, obtained by
A Fusco26 was used as positive control. In total, 50 nM of duplex RNAs were
co-transfected with the reporter plasmid DNA. After 24 h, cells were lysed and
luciferase expression was measured with the Dual Luciferase Assay kit (Promega)
using a luminescence counter (1420 Victor Light, PerkinElmer, Waltham, MA, USA).
Immunofluorescence analysis. For labeling with mAb to myosin heavy
chain (MF20), cultures were fixed with a mixture of 3.5% formaldehyde, 70%
ethanol and 5% acetic acid and washed thoroughly before incubation with antibody.
The samples were examined with an Olympus AX70 immunofluorescence
microscope. Images were recorded on an Olympus XM10 camera and processed
using the Olympus CellSens Standard 1.8.1 software. Cell scoring was carried out
using the public domain software ImageJ.
Whole-cell extracts and western blot analysis. Cells were lysed in
RIPA buffer (140 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 15 mM Hepes, pH 7.2, also
containing 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS) supplemented with a
cocktail of protease inhibitors. Western blots were carried out using horseradish
peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies and revealed with
a chemiluminescence detection system by Thermo Scientific. Imaging and
quantitation of the bands were carried out by ChemiDoc XRS Western Blot Imagin
System using the ImageLab 4.0 software (Bio-Rad, Hercules, CA, USA).
Statistical analysis. Variables were analyzed by Student’s t-test and a
probability value of P⩽ 0.05 was deemed statistically significant. Values are
expressed as average±S.E.
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